Indoleamine 2,3-Dioxygenase (IDO) Enzyme Links Innate Immunity and Altered T-Cell Differentiation in Non-ST Segment Elevation Acute Coronary Syndrome
暂无分享,去创建一个
F. Crea | A. Severino | D. D’Amario | F. Trotta | G. Liuzzo | D. Pedicino | A. Giglio | C. Zara | D. Flego | A. Ruggio | C. Lucci | R. Vinci | E. Pisano | G. La Rosa | L. Biasucci | A. F. Giglio | Claudia Lucci
[1] D. Hawiger,et al. Dendritic Cells As Inducers of Peripheral Tolerance. , 2017, Trends in immunology.
[2] L. Brochez,et al. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. , 2017, European journal of cancer.
[3] M. Zou,et al. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases , 2017, Cellular and Molecular Life Sciences.
[4] F. Crea,et al. Adaptive Immunity Dysregulation in Acute Coronary Syndromes: From Cellular and Molecular Basis to Clinical Implications. , 2016, Journal of the American College of Cardiology.
[5] Inhye Park,et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development , 2015, Proceedings of the National Academy of Sciences.
[6] R. Baumgartner,et al. Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice. , 2015, Cardiovascular research.
[7] F. Crea,et al. Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes. , 2015, Journal of the American College of Cardiology.
[8] A. Orekhov,et al. Dendritic cells: a double-edge sword in atherosclerotic inflammation. , 2015, Current pharmaceutical design.
[9] G. Mellgren,et al. Associations of Plasma Kynurenines With Risk of Acute Myocardial Infarction in Patients With Stable Angina Pectoris , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[10] F. Crea,et al. Altered CD31 expression and activity in helper T cells of acute coronary syndrome patients , 2014, Basic Research in Cardiology.
[11] F. Crea,et al. Identification of unique adaptive immune system signature in acute coronary syndromes. , 2013, International journal of cardiology.
[12] G. Fedele,et al. Chlamydia pneumoniae modulates human monocyte-derived dendritic cells functions driving the induction of a Type 1/Type 17 inflammatory response. , 2013, Microbes and infection.
[13] G. Hansson,et al. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. , 2012, European heart journal.
[14] Esther Lutgens,et al. Plasmacytoid Dendritic Cells Protect Against Atherosclerosis by Tuning T-Cell Proliferation and Activity , 2011, Circulation research.
[15] G. Hansson,et al. The immune system in atherosclerosis , 2011, Nature Immunology.
[16] Jeff E. Mold,et al. Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.
[17] T. Lehtimäki,et al. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere Vascular Study , 2010, Annals of medicine.
[18] Lei Wang,et al. Toll‐like receptor‐4 and mitogen‐activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome , 2008, Immunology.
[19] Yong Chen,et al. The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.
[20] D. Fuchs,et al. Induction of Indoleamine 2,3-Dioxygenase in Vascular Smooth Muscle Cells by Interferon-γ Contributes to Medial Immunoprivilege1 , 2007, The Journal of Immunology.
[21] A. Rebuzzi,et al. Unusual CD4+CD28nullT Lymphocytes and Recurrence of Acute Coronary Events , 2007 .
[22] A. Hamsten,et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome , 2007, Heart.
[23] A. Rebuzzi,et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. , 2007, Journal of the American College of Cardiology.
[24] M. Chiariello,et al. Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque: Evidence for a Local, Intracoronary Immunologic Mechanism , 2006, Circulation.
[25] R. Steinman,et al. Dendritic cells: translating innate to adaptive immunity. , 2006, Current topics in microbiology and immunology.
[26] Tian Yuan,et al. Differentiation of dendritic cells in monocyte cultures isolated from patients with unstable angina. , 2004, International journal of cardiology.
[27] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[28] Tim R Mosmann,et al. Dendritic cells: the immune information management experts , 2004, Nature Immunology.
[29] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[30] R. Frye,et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. , 2000, Circulation.
[31] Milton W. Taylor,et al. Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.
[32] P. Kalinski,et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.
[33] K. Kanmatsuse,et al. [Pathogenesis of acute coronary syndromes]. , 1998, Nihon rinsho. Japanese journal of clinical medicine.